Dr. Reddy's Laboratories rose 2.5% to Rs 4,408 after the pharmaceutical company said that its tocilizumab biosimilar candidate, DRL_TC has completed its primary and secondary endpoints in a Phase 1 study. This Phase I study used a subcutaneous formulation to evaluate the pharmacokinetic equivalence, safety, and immunogenicity of the company's Tocilizumab biosimilar candidate in comparison to reference products, it added.“The Phase 1 study entitled ‘A Single Dose, Double-Blind, Two-Period, Crossover, Comparative Pharmacokinetic Study of Three Tocilizumab Products Administered by the Subcutaneous Route to Normal Healthy Volunteers’ met all primary and secondary endpoints."The successful outcome of this study represents an important milestone in Dr Reddy's commitment to making high-quality biosimilar products more accessible and affordable to healthcare providers and patients around the world," the company said.
Read more